S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Closing prices for crude oil, gold and other commodities
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
You Can Follow BlackRock’s Market View for Your Money
NASDAQ:DVAX

Dynavax Technologies (DVAX) Stock Price, News & Analysis

$11.84
-0.17 (-1.42%)
(As of 04/12/2024 ET)
Today's Range
$11.76
$12.02
50-Day Range
$11.70
$13.14
52-Week Range
$10.06
$15.15
Volume
1.94 million shs
Average Volume
1.94 million shs
Market Capitalization
$1.53 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00

Dynavax Technologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
110.8% Upside
$25.00 Price Target
Short Interest
Bearish
13.90% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
1.14mentions of Dynavax Technologies in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$262,322 Sold Last Quarter
Proj. Earnings Growth
79.17%
From $0.24 to $0.43 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.37 out of 5 stars

Medical Sector

352nd out of 2,784 stocks

Pharmaceutical Preparations Industry

127th out of 1,293 stocks

DVAX stock logo

About Dynavax Technologies Stock (NASDAQ:DVAX)

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

DVAX Stock Price History

DVAX Stock News Headlines

3 Biotech Buys Under $15
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Dynavax Technologies: Still A Believer
Dynavax Technologies: Still A Believer
Dynavax: Holding Firm Despite Its Missing Cash Cow
Dynavax: Holding Firm Despite Its Missing Cash Cow
Bitcoin Rockets To Record High But Buy THIS Instead
Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…
Dynavax Technologies Corporation (DVAX)
Dynavax Technologies Corp (DYF1.DU)
Dynavax’s Strong Financials and Promising Pipeline Secure Buy Rating
Dynavax Technologies: Q4 Earnings Insights
Here's what Wall Street expects from Dynavax Technologies's earnings
Dynavax Q4 2023 Earnings Preview
DVAX Jul 2024 18.000 call
See More Headlines
Receive DVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Dynavax Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
4/12/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:DVAX
CUSIP
26815810
Employees
408
Year Founded
1996

Price Target and Rating

Average Stock Price Target
$25.00
High Stock Price Target
$28.00
Low Stock Price Target
$20.00
Potential Upside/Downside
+110.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-6,390,000.00
Pretax Margin
-1.88%

Debt

Sales & Book Value

Annual Sales
$232.28 million
Book Value
$4.81 per share

Miscellaneous

Free Float
125,912,000
Market Cap
$1.53 billion
Optionable
Optionable
Beta
1.26

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

DVAX Stock Analysis - Frequently Asked Questions

Should I buy or sell Dynavax Technologies stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" DVAX shares.
View DVAX analyst ratings
or view top-rated stocks.

What is Dynavax Technologies' stock price target for 2024?

4 Wall Street research analysts have issued 1 year price targets for Dynavax Technologies' shares. Their DVAX share price targets range from $20.00 to $28.00. On average, they expect the company's stock price to reach $25.00 in the next twelve months. This suggests a possible upside of 110.8% from the stock's current price.
View analysts price targets for DVAX
or view top-rated stocks among Wall Street analysts.

How have DVAX shares performed in 2024?

Dynavax Technologies' stock was trading at $13.98 at the beginning of 2024. Since then, DVAX shares have decreased by 15.2% and is now trading at $11.86.
View the best growth stocks for 2024 here
.

When is Dynavax Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our DVAX earnings forecast
.

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) announced its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by $0.29. The biopharmaceutical company earned $108.27 million during the quarter, compared to analysts' expectations of $77.30 million. Dynavax Technologies had a negative trailing twelve-month return on equity of 1.08% and a negative net margin of 2.75%. During the same period in the previous year, the business earned ($0.15) EPS.

What is Eddie Gray's approval rating as Dynavax Technologies' CEO?

13 employees have rated Dynavax Technologies Chief Executive Officer Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among the company's employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 61.0% of employees surveyed would recommend working at Dynavax Technologies to a friend.

What other stocks do shareholders of Dynavax Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Who are Dynavax Technologies' major shareholders?

Dynavax Technologies' stock is owned by a variety of retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.18%). Insiders that own company stock include Andrew A F Hack, David F Novack, David F Novack, Francis Cano, Justin Burgess, Robert Janssen and Ryan Spencer.
View institutional ownership trends
.

How do I buy shares of Dynavax Technologies?

Shares of DVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:DVAX) was last updated on 4/12/2024 by MarketBeat.com Staff

From Our Partners